Comparative Pharmacology
Head-to-head clinical analysis: PRISMASOL BGK 4 0 IN PLASTIC CONTAINER versus PRISMASOL BGK 4 0 1 2 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRISMASOL BGK 4 0 IN PLASTIC CONTAINER versus PRISMASOL BGK 4 0 1 2 IN PLASTIC CONTAINER.
PRISMASOL BGK 4/0 IN PLASTIC CONTAINER vs PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Hemodialysis solution components correct electrolyte imbalances and acid-base disturbances via diffusion and ultrafiltration across a semipermeable membrane.
Prismasol BGK 4/0/1.2 is a bicarbonate-buffered hemofiltration solution used in continuous renal replacement therapy (CRRT). It provides electrolyte replacement and buffer to correct metabolic acidosis, maintain electrolyte balance, and remove waste products through hemofiltration or hemodiafiltration.
Renal replacement therapy for acute kidney injuryChronic kidney disease requiring hemodialysis
Continuous renal replacement therapy (CRRT) for acute kidney injuryHemofiltrationHemodiafiltrationHemodialysis in patients with fluid and electrolyte imbalances
Intravenous continuous renal replacement therapy (CRRT) using Prismasol BGK 4/0. Typical flow rate: dialysate and replacement fluid at 2000-3000 mL/h, adjusted to achieve desired solute clearance and fluid balance. Dose individualized based on patient size, metabolic rate, and clinical status.
Dosing is individualized based on patient's fluid status, electrolyte levels, and acid-base balance. Typically, the infusion rate is titrated to achieve desired ultrafiltration and clearance goals, often ranging from 1 to 3 L/hour in adults, adjusted according to clinical response.
None Documented
None Documented
Not applicable as a replacement solution; components follow endogenous kinetics. For bicarbonate buffer, half-life is minutes due to rapid equilibration; for electrolytes, half-life depends on CRRT clearance.
Not applicable as a drug; the half-life of infused components is governed by the dialysis session duration and the body's own metabolic clearance. Glucose half-life in circulation is ~1-2 hours, but in the context of dialysis, the solution is ultrafiltered and removed continuously.
Not metabolized; components are excreted or redistributed during dialysis.
Prismasol is not metabolized; components are electrolytes and buffer (bicarbonate) that participate in normal physiological processes. Bicarbonate is converted to carbon dioxide and water via carbonic anhydrase.
PRISMASOL BGK 4/0 is a replacement solution for continuous renal replacement therapy (CRRT); its components (electrolytes, buffer) are primarily eliminated via the CRRT circuit (ultrafiltration/dialysis). Renal excretion negligible in anuric patients; biliary/fecal elimination not clinically relevant.
Prismasol BGK 4/0/1.2 is a dialysis solution; its components (glucose, electrolytes, buffer) are not systemically absorbed in significant amounts. The solution is removed via the dialysis effluent. No renal/biliary/fecal elimination applies; the solutes are cleared by the dialysis process itself.
<10% for all components (sodium, potassium, magnesium, chloride, bicarbonate/gluconate); no significant protein binding.
Components (glucose, calcium, magnesium, lactate, sodium, chloride) are minimally bound to plasma proteins (<10%).
Total body water (~0.6 L/kg) for electrolytes; distributes throughout extracellular fluid (0.2 L/kg) for bicarbonate.
Not applicable; the solution distributes into the peritoneal cavity and equilibrates with plasma water. For electrolytes and glucose, Vd approximates extracellular fluid volume (~0.2 L/kg).
100% intravenously; not administered via other routes.
100% when administered intraperitoneally; all components are available for dialysis exchange.
No dose adjustment required; product is specifically designed for use in patients with acute kidney injury requiring CRRT. Dose (flow rate) adjusted based on residual renal function and treatment goals. In patients with preserved renal function not requiring dialysis, use not indicated.
Dosing is inherently titrated to renal replacement therapy parameters; no separate renal adjustment necessary as the therapy replaces renal function.
No specific guidance; use with caution in hepatic impairment. Monitor electrolytes and acid-base status. Dose adjustment may be needed if severe hepatic failure impacts metabolic parameters.
No adjustment required; constituents are not hepatically metabolized.
Intravenous CRRT: dialysate and replacement fluid flow rates typically 2000-3000 mL/h/1.73 m², adjusted for body surface area. Exact rate determined by nephrologist based on pediatric patient’s size and clinical needs.
Use in pediatric patients should be based on body weight and clinical condition; dosing rates are typically lower (e.g., 20–50 mL/kg/hour) and require careful monitoring.
Elderly patients: use standard CRRT dosing, with careful monitoring for fluid overload and electrolyte imbalances due to decreased renal reserve. Dose adjustments of flow rate may be necessary based on clinical status.
Standard adult protocols apply; however, elderly patients may be more sensitive to fluid shifts and electrolyte changes, necessitating close monitoring.
None
Not for intravenous injection directly into the body; for extracorporeal use only. Must be used in a controlled CRRT system with proper monitoring.
["Monitor serum electrolytes, acid-base status, and fluid balance closely","Risk of hyperkalemia if potassium-containing solutions are used inappropriately","Risk of aluminum toxicity in patients with renal failure","Use with caution in patients with severe respiratory alkalosis"]
["Monitor serum electrolytes, acid-base status, and fluid balance closely","Risk of electrolyte disturbances (hypokalemia, hyperkalemia, hypophosphatemia, hyperphosphatemia)","Risk of metabolic alkalosis or acidosis","Do not administer unless solution is clear and container undamaged","Discard unused portion; single-use container","Use aseptic technique during connection"]
["Severe hypokalemia","Metabolic alkalosis","Hypocalcemia","Hyperphosphatemia with calcium-containing solutions"]
["Severe hypercalcemia","Severe metabolic alkalosis","Known hypersensitivity to any component","Contraindicated if adequate anticoagulation cannot be maintained (due to circuit clotting risk)"]
Data Pending Review
Data Pending Review
No direct food interactions. However, patients on CRRT may have dietary restrictions based on underlying condition (e.g., renal diet). Monitor glucose levels if diabetic due to glucose content.
No direct food interactions. However, dietary restrictions may be necessary based on underlying renal failure and electrolyte levels. Patients should follow a renal-specific diet as advised by their clinician, typically restricting potassium, phosphorus, and sodium.
PRISMASOL BGK 4/0 IN PLASTIC CONTAINER is a sterile, nonpyrogenic solution for continuous renal replacement therapy (CRRT). It contains electrolytes and glucose but no drugs. As a physiological solution, it is not associated with teratogenic risk. However, the underlying condition requiring CRRT (e.g., severe acute kidney injury, electrolyte imbalances) poses significant maternal and fetal risks. In pregnancy, CRRT may be necessary for life-threatening conditions; the potential benefits outweigh theoretical risks. No specific teratogenic effects are expected from the solution itself. First trimester: No known fetal harm. Second and third trimesters: No known harm, but maternal acid-base and electrolyte disturbances requiring CRRT can adversely affect fetal outcomes.
PRISMASOL BGK 4/0/1.2 is a dialysis solution for continuous renal replacement therapy (CRRT). It is not systemically absorbed; thus, no direct fetal exposure occurs. However, maternal metabolic acidosis or electrolyte disturbances during CRRT may pose risks. No teratogenic effects are expected, but use in pregnancy should be based on maternal necessity.
PRISMASOL BGK 4/0 IN PLASTIC CONTAINER is a physiological solution; components are already present in breast milk. No M/P ratio available. Use during breastfeeding is considered safe as it does not contain drugs that would transfer significantly. Maternal electrolyte and fluid balance should be maintained to ensure adequate milk production.
Not systemically absorbed; therefore, no excretion into breast milk. M/P ratio is not applicable. Compatible with breastfeeding.
In pregnancy, increased plasma volume and glomerular filtration rate do not alter the composition of this solution, as it is a fixed electrolyte/glucose solution. No dose adjustment is needed for the solution itself. However, CRRT prescription (e.g., flow rates, dialysate composition) may require adjustment to account for maternal-fetal hemodynamics and to avoid rapid electrolyte shifts. Close monitoring of maternal blood pressure and fluid status is essential.
No dose adjustment needed for PRISMASOL BGK 4/0/1.2 as it is a replacement solution. However, CRRT prescription (flow rates, ultrafiltration) may require adjustment to maintain metabolic and volume homeostasis during pregnancy.
Category C
Category C
Prismasol BGK 4/0 is a bicarbonate-buffered hemofiltration solution used in continuous renal replacement therapy (CRRT). It contains glucose (4 g/L) and no potassium. Monitor serum potassium closely; hypokalemia may develop requiring supplementation. The solution has a physiological pH; ensure correct connection to avoid air embolism. Adjust fluid removal rate based on patient's hemodynamic status and fluid balance goals.
PRISMASOL BGK 4/0/1.2 is a sterile, non-pyrogenic solution for continuous renal replacement therapy (CRRT). It contains lactate as a buffer and is contraindicated in patients with severe lactic acidosis. Monitor serum electrolytes, acid-base status, and glucose levels frequently. The solution has 4 g/L glucose, which may cause hyperglycemia in diabetic patients. Do not use if precipitate or discoloration is present. Priming volume and flow rates must be adjusted based on patient weight and clinical status.
This solution is used during a continuous blood filtration procedure to help remove waste products from your blood.You will be closely monitored for fluid balance, electrolytes, and vital signs throughout treatment.Report any symptoms like muscle cramps, weakness, or palpitations, as these may indicate electrolyte imbalances.Do not eat or drink unless instructed by your healthcare team, as dietary intake may affect your treatment.
This solution is used during continuous dialysis to help remove waste products and excess fluids from your blood.Your healthcare team will closely monitor your blood levels of electrolytes, sugar, and acid-base balance during treatment.Inform your doctor if you have diabetes, as the solution contains sugar that may affect your blood glucose levels.Report any signs of low or high blood sugar, such as shakiness, sweating, confusion, or increased thirst.The solution is given through a special catheter in a vein; avoid touching the insertion site.